Scarica l'app Stockscreener
232.10
1.34%
+3.07
Dopo l'orario di chiusura:
232.50
0.40
+0.17%
Precedente Chiudi:
$229.03
Aprire:
$230.88
Volume 24 ore:
304.72K
Capitalizzazione di mercato:
$11.96B
Reddito:
$4.13B
Utile/perdita netta:
$474.62M
Rapporto P/E:
24.61
EPS:
9.43
Flusso di cassa netto:
$365.37M
1 W Prestazione:
-0.20%
1M Prestazione:
-14.34%
6M Prestazione:
+34.48%
1 anno Prestazione:
+22.08%
Intervallo 1D:
$230.31
$233.28
Portata 52W:
$161.65
$275.00
Charles River Laboratories International Inc. Stock (CRL) Company Profile
Nome
Charles River Laboratories International Inc.
Settore
Industria
Telefono
781-222-6000
Indirizzo
251 Ballardvale Street, Wilmington, MA
Charles River Laboratories International Inc. Stock (CRL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-02-15 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-09-13 | Iniziato | TD Cowen | Market Perform |
| 2023-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2023-02-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-12 | Downgrade | Jefferies | Buy → Hold |
| 2022-09-30 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-08-04 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Iniziato | Guggenheim | Neutral |
| 2022-04-25 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-07 | Iniziato | Stephens | Overweight |
| 2022-02-17 | Reiterato | BofA Securities | Buy |
| 2022-02-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-02-17 | Reiterato | Deutsche Bank | Buy |
| 2022-02-17 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-17 | Reiterato | UBS | Buy |
| 2021-08-05 | Ripresa | Credit Suisse | Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-09-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-07-01 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-05-13 | Aggiornamento | UBS | Neutral → Buy |
| 2020-04-21 | Downgrade | Jefferies | Buy → Hold |
| 2020-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Iniziato | Deutsche Bank | Buy |
| 2020-02-18 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-10-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Iniziato | SVB Leerink | Outperform |
| 2019-04-30 | Ripresa | Evercore ISI | Outperform |
| 2018-12-14 | Iniziato | Deutsche Bank | Buy |
| 2018-10-09 | Iniziato | UBS | Neutral |
| 2018-08-23 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Aggiornamento | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Aggiornamento | SunTrust | Hold → Buy |
Mostra tutto
Charles River Laboratories International Inc. Borsa (CRL) Ultime notizie
ICLR vs. CRL: Which Stock Is the Better Value Option?
Zacks Investment Research
Teladoc (TDOC) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
Charles River (CRL) to Report Q1 Earnings: Here's What to Expect
Zacks Investment Research
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Zacks Investment Research
Here's Why You Should Retain Charles River (CRL) Stock Now
Zacks Investment Research
ICLR or CRL: Which Is the Better Value Stock Right Now?
Zacks Investment Research
Charles River Laboratories International Inc. Azioni (CRL) Dati Finanziari
Charles River Laboratories International Inc. (CRL) Reddito 2024
CRL ha riportato un ricavo (TTM) di $4.13 miliardi per il trimestre terminato il 2023-12-31, un +3.86% salita anno su anno.
Charles River Laboratories International Inc. (CRL) Reddito netto 2024
CRL l'utile netto (TTM) è stato di $474.62 milioni per il trimestre terminato il 2023-12-31, un -2.39% diminuire anno su anno.
Charles River Laboratories International Inc. (CRL) Flusso di cassa 2024
CRL ha registrato un flusso di cassa disponibile (TTM) di $365.37 milioni per il trimestre conclusosi con 2023-12-31, un +23.89% aumento anno su anno.
Charles River Laboratories International Inc. (CRL) Utile per azione 2024
L'utile per azione (TTM) di CRL è stato pari a $9.23 per il trimestre terminato il 2023-12-31, un -2.53% declino anno su anno.
Charles River Laboratories International Inc. Azioni (CRL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Knell Michael Gunnar | CSVP&Chief Accounting Officer |
Mar 04 '24 |
Sale |
261.05 |
2,750 |
717,890 |
7,832 |
| Creamer Victoria L | EVP & Chief People Officer |
Feb 29 '24 |
Sale |
253.70 |
5,000 |
1,268,500 |
13,550 |
| Parisotto Shannon M | CEVP, Disc & Safety Assessment |
Feb 29 '24 |
Sale |
253.45 |
3,786 |
959,545 |
4,792 |
| Barbo William D | Corporate Executive VP & CCO |
Feb 22 '24 |
Sale |
248.50 |
4,050 |
1,006,425 |
22,879 |
| Parisotto Shannon M | CEVP, Disc & Safety Assessment |
Feb 15 '24 |
Option Exercise |
144.67 |
5,882 |
850,949 |
8,478 |
| Parisotto Shannon M | CEVP, Disc & Safety Assessment |
Feb 15 '24 |
Sale |
241.20 |
5,882 |
1,418,767 |
2,596 |
| LaPlume Joseph W | EVP, Corp Strategy & Develop |
Feb 15 '24 |
Sale |
238.93 |
838 |
200,223 |
24,620 |
| FOSTER JAMES C | Chairman, President and CEO |
Jan 29 '24 |
Option Exercise |
144.67 |
17,436 |
2,522,466 |
227,827 |
| Girshick Birgit | Corporate Executive VP & COO |
Jan 10 '24 |
Option Exercise |
215.19 |
5,916 |
1,273,064 |
50,365 |
| Creamer Victoria L | EVP & Chief People Officer |
Dec 14 '23 |
Option Exercise |
136.70 |
5,526 |
755,388 |
22,032 |
2.91%
1.35%
Capitalizzazione:
|
Volume (24 ore):